WKYMVm is a selective agonist for formyl peptide receptors FPR1, FPR2 (EC50 = 75 pM) and FPR3 (EC50 = 3 nM) when expressed on immune cells. WKYMVm induces Ca2+ mobilization and superoxide production in, and chemotaxic migration of, monocytes and neutrophils. WKYMVm has pleiotropic anti-inflammatory, pro-angiogenic, anti-apoptotic and immunomodulatory effects in various animal models of sepsis, ulcerative colitis, myocardial infarction, ischemic hindlimb and diabetic cutaneous wound healing.
